Ambu shares jump 6% on strong Q4 growth, upbeat guidance

Ambu reported Q4 revenue of DKK 1,700 million, up 13.9% organically, while EBIT rose to DKK 293 million from DKK 147 million and margin expanded to 17.2% from 10%. For fiscal 2026/27, it forecast 9.5%–11.5% organic revenue growth and a 13%–15% EBIT margin, and proposed returning DKK 551 million through a DKK 151 million dividend and DKK 400 million share buyback. Shares rose 6% after the results and outlook.

Analysis

The key debate is earnings quality, not whether Q4 was strong. A 17.2% quarterly EBIT margin sits well above the 13%–15% FY26/27 outlook; tariff reclaims helped Q4, so treating that quarter as the new run rate risks overestimating underlying operating leverage. The guidance is the more useful anchor until Ambu shows that volume growth can convert into margins without those benefits.

Endoscopy is the main structural upside and the main execution risk. Continued single-use adoption could take procedure share from reusable platforms and support Ambu’s growth, but established endoscopy vendors such as Olympus and Boston Scientific have incentives and distribution to defend their franchises. Respiratory growth after SureSight Mobile is encouraging, but one quarter does not establish durable product adoption. The weaker Anesthesia result also makes the growth mix important: headline growth can remain healthy while the portfolio’s less buoyant lines dilute margins.

Near term, the 6% post-results rise raises the bar for follow-through; the proposed buyback may support demand but is not evidence of improved fundamentals. Over the next 1–3 months, watch organic Endoscopy growth, EBIT margin excluding tariff effects, and confirmation that the buyback is executed. Over 6–18 months, the thesis depends on repeatable single-use adoption and profitable growth. A margin trend settling below the guided range, or a material slowdown in Endoscopy, would falsify the constructive view.

Key Decisions for Investors

• Do not chase the initial rally. Keep AMBU.B on a conditional long watchlist; consider entry after price consolidation only if subsequent reporting supports Endoscopy growth and underlying margins within the FY26/27 outlook.
• For existing longs, use the 13%–15% EBIT-margin outlook—not Q4’s 17.2%—as the operating benchmark. Reduce exposure if margins weaken below the guided range or management attributes performance increasingly to temporary tariff effects.
• Track quarterly Endoscopy organic growth, product adoption evidence for SureSight Mobile, and buyback execution. If growth decelerates materially while margins fail to hold guidance, reassess the premium-growth thesis; otherwise the buyback and recurring procedure adoption can support the medium-term case.
• Avoid a competitor pair trade for now: the article provides no market-share, pricing, or valuation evidence to size a short against Olympus or Boston Scientific. Revisit only if Ambu’s growth gains coincide with verifiable share loss or weaker outlooks from incumbents.